An irregular heartbeat, which is scientifically termed as a cardiac arrhythmia, can begin at a moment’s notice before rapidly becoming worse.
A couple of decades ago, in the ‘60s, a physician by the name of L. Julian Haywood found a way to monitor an individual’s heart continuously, watching for a change in its rhythm and then alerting doctors and nurses when an anomaly was found.
Before that, in 1956, Haywood was in year two of his internal medicine residency at the Los Angeles County General Hospital. He had concluded his residency at the Howard University and the University of Virginia before deciding to specialize in cardiology.
However, he was disappointed to learn that the hospital had no cardiology review conferences where students and doctors could talk about any new developments or patients; neither did it have clinical cardiology rounds nor formal teaching in cardiology. This was despite the fact that the hospital’s mortality rate among patients who had heart attacks was 35%.
Despite the many inventions that had been designed over centuries ago to monitor the activity of an individual’s heart, including the capillary electrometer, which was invented in the early 1870s by Gabriel Lippmann, and the string galvanometer, invented by Willem Einthoven in 1893, cardiology was still not considered a specialty when Haywood was concluding his residency at the L.A County General Hospital.
It wasn’t until 1966 that Haywood began a coronary care unit. He also secured funds from the American Heart Association’s L.A. chapter to begin a cardiology nurse training program. With the objective being to reduce the mortality rate of heart attack victims, Haywood began to look for a reliable way that would allow physicians to monitor a patient’s heart and record any anomalies.
Together with his associates, Haywood developed a digital heart monitor prototype in 1969 and began using it in the coronary care unit. This helped significantly reduce the cardiac patients’ mortality rates in the unit.
Decades later in 2018, Haywood published an article that discussed the various factors that led to the significant decline in the heart disease death rate in the county of Los Angeles. In the article, he deduced that the establishment of coronary care units in the ’60s helped bring focus on cardiology, which led to advancements being made in bypass surgery, angioplasty and angiography as well as better medications to control cholesterol and blood pressure.
In addition to this, the success of cardiothoracic surgery and cardiology programs at various institutions encouraged more research in this field to be conducted, which led to various lifesaving inventions such as heart valve replacements and pacemakers.
When talking about heart health, it is almost inevitable that one will think about brain health (due to heart disease increasing the chance of stroke, for example), and lots of companies have brought advances to the neurological sector. A clear example is Brain Scientific Inc. (OTCQB: BRSF), which so far has two devices (NeuroEEG and NeuroCap) that are revolutionizing the EEG market since they are disposable and provide diagnostic results faster.
NOTE TO INVESTORS: The latest news and updates relating to Brain Scientific Inc. (OTCQB: BRSF) are available in the company’s newsroom at https://ibn.fm/BRSF
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.biomedwire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.
immunotherapy against cancer. In many of these cases, the inflammation recurs, and the treatment impacts…
According to a survey conducted by Gallup Center and West Health, most Americans have no…
A study conducted recently in Ohio has found that wastewater can be a vital provider…
UC San Francisco-based scientists have developed a new immunotherapy that was successful in wiping out…
Immunotherapy has transformed cancer treatment, but the approach still faces challenges like lengthy preparation time…
The palpable euphoria surrounding the election of Democratic healthcare professionals to key positions in the…